Antisense Therapeutics Limited Stock Working Capital

ATHJF Stock  USD 0.04  0.00  0.00%   
Antisense Therapeutics Limited fundamentals help investors to digest information that contributes to Antisense Therapeutics' financial success or failures. It also enables traders to predict the movement of Antisense Pink Sheet. The fundamental analysis module provides a way to measure Antisense Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Antisense Therapeutics pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Antisense Therapeutics Limited Company Working Capital Analysis

Antisense Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

 = 

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Antisense Therapeutics Working Capital

    
  4 M  
Most of Antisense Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Antisense Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition

In accordance with the company's disclosures, Antisense Therapeutics Limited has a Working Capital of 4 M. This is 99.06% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The working capital for all United States stocks is 99.73% higher than that of the company.

Did you try this?

Run Economic Indicators Now

   

Economic Indicators

Top statistical indicators that provide insights into how an economy is performing
All  Next Launch Module

Antisense Fundamentals

About Antisense Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Antisense Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Antisense Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Antisense Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Antisense Pink Sheet

Antisense Therapeutics financial ratios help investors to determine whether Antisense Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Antisense with respect to the benefits of owning Antisense Therapeutics security.